Published in Angiogenesis on June 01, 2010
Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev (2010) 2.37
Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals. Chem Soc Rev (2011) 1.36
Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications. Int J Nanomedicine (2012) 1.12
Functional imaging in adult and paediatric brain tumours. Nat Rev Clin Oncol (2012) 1.05
Computed tomography imaging of primary lung cancer in mice using a liposomal-iodinated contrast agent. PLoS One (2012) 1.00
A concise review of magnetic resonance molecular imaging of tumor angiogenesis by targeting integrin αvβ3 with magnetic probes. Int J Nanomedicine (2013) 0.99
Nanoparticles for imaging: top or flop? Radiology (2014) 0.97
Incorporation of paramagnetic, fluorescent and PET/SPECT contrast agents into liposomes for multimodal imaging. Biomaterials (2012) 0.96
Nanotechnology-based approaches in anticancer research. Int J Nanomedicine (2012) 0.93
A diaCEST MRI approach for monitoring liposomal accumulation in tumors. J Control Release (2014) 0.91
Non-invasive molecular imaging for preclinical cancer therapeutic development. Br J Pharmacol (2013) 0.91
Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles. Int J Nanomedicine (2013) 0.88
Using magnetic resonance imaging and spectroscopy in cancer diagnostics and monitoring: preclinical and clinical approaches. Cancer Biol Ther (2011) 0.86
Internalization of paramagnetic phosphatidylserine-containing liposomes by macrophages. J Nanobiotechnology (2012) 0.84
Design and Application of Magnetic-based Theranostic Nanoparticle Systems. Recent Pat Biomed Eng (2013) 0.83
Imaging of angiogenesis. Angiogenesis (2010) 0.82
Development and application of a multimodal contrast agent for SPECT/CT hybrid imaging. Bioconjug Chem (2011) 0.81
Integrin-mediated cell-matrix interaction in physiological and pathological blood vessel formation. J Oncol (2011) 0.79
Surfactant-Stripped Frozen Pheophytin Micelles for Multimodal Gut Imaging. Adv Mater (2016) 0.79
Phase separation behavior of mixed lipid systems at neutral and low pH: coarse-grained simulations with DMD/LIME. Langmuir (2015) 0.75
Multimodal targeted high relaxivity thermosensitive liposome for in vivo imaging. Sci Rep (2015) 0.75
Accumulation of nano-sized particles in a murine model of angiogenesis. Biochem Biophys Res Commun (2013) 0.75
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 15.70
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 13.94
Angiogenesis as a therapeutic target. Nature (2005) 11.89
Tumor angiogenesis. N Engl J Med (2008) 11.30
Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov (2005) 10.97
Arg-Gly-Asp: a versatile cell recognition signal. Cell (1986) 7.89
Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol (2007) 7.75
Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol (1965) 7.58
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett (1990) 5.14
Tumor regression by targeted gene delivery to the neovasculature. Science (2002) 4.78
Amide proton transfer (APT) contrast for imaging of brain tumors. Magn Reson Med (2003) 4.57
High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem (1999) 4.41
Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer (2008) 4.27
Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev (1999) 4.02
Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol (1997) 3.89
Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med (1998) 3.85
Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res (2001) 3.01
Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev (2000) 2.94
Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res (2003) 2.70
Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J (2007) 2.38
Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res (2002) 2.38
In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. Cancer Res (2007) 2.19
MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem (2004) 2.15
Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol (2008) 2.05
MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J (2005) 2.03
Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res (2007) 2.01
Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med (2001) 2.00
18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol (2004) 1.99
Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheum (2006) 1.98
Camelid immunoglobulins and nanobody technology. Vet Immunol Immunopathol (2008) 1.90
Endogenous angiogenesis inhibitors. APMIS (2004) 1.89
Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology (2008) 1.88
Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn Reson Med (2004) 1.83
Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler Thromb Vasc Biol (2007) 1.78
Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J Clin Invest (2009) 1.78
Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide. Mol Imaging (2004) 1.76
Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chemistry (2003) 1.69
Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. FASEB J (2008) 1.67
Imaging of integrin alphavbeta3 expression. Cancer Metastasis Rev (2008) 1.56
Virus-based nanoparticles (VNPs): platform technologies for diagnostic imaging. Adv Drug Deliv Rev (2006) 1.50
A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug Chem (2004) 1.47
Macromolecular MRI contrast agents for imaging tumor angiogenesis. Eur J Radiol (2006) 1.46
Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. FASEB J (2008) 1.41
Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging (2006) 1.39
Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics. Ann Biomed Eng (2009) 1.39
Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin Drug Deliv (2006) 1.35
High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.30
Magnetic and fluorescent nanoparticles for multimodality imaging. Nanomedicine (Lond) (2007) 1.28
Anginex, a designed peptide that inhibits angiogenesis. Biochem J (2001) 1.27
A high relaxivity Gd(III)DOTA-DSPE-based liposomal contrast agent for magnetic resonance imaging. Eur J Pharm Biopharm (2008) 1.23
Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J (2007) 1.23
Relaxivity of liposomal paramagnetic MRI contrast agents. MAGMA (2005) 1.22
Contrast agents and applications to assess tumor angiogenesis in vivo by magnetic resonance imaging. Curr Med Chem (2007) 1.20
A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J Control Release (2006) 1.19
Modulation of the pharmacokinetics of macromolecular contrast material by avidin chase: MRI, optical, and inductively coupled plasma mass spectrometry tracking of triply labeled albumin. Magn Reson Med (2003) 1.16
Synergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett (2010) 1.16
High sensitivity: high-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 model. Invest Radiol (2009) 1.15
Rapid blood clearance of biotinylated IgG after infusion of avidin. J Nucl Med (1989) 1.15
Bimodal paramagnetic and fluorescent liposomes for cellular and tumor magnetic resonance imaging. Bioconjug Chem (2007) 1.13
Modified natural nanoparticles as contrast agents for medical imaging. Adv Drug Deliv Rev (2009) 1.12
Liposomal Gd-DTPA: preparation and characterization of relaxivity. Radiology (1989) 1.11
Polymersomes: a new multi-functional tool for cancer diagnosis and therapy. Methods (2008) 1.09
Tissue distribution of avidin and streptavidin injected to mice. Effect of avidin carbohydrate, streptavidin truncation and exogenous biotin. Eur J Biochem (1990) 1.09
The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J (2002) 1.09
Paramagnetic liposomes as MRI contrast agents: influence of liposomal physicochemical properties on the in vitro relaxivity. Magn Reson Imaging (1999) 1.06
Three-compartment T1 relaxation model for intracellular paramagnetic contrast agents. Magn Reson Med (2009) 1.05
Liposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicity. Biochim Biophys Acta (2005) 1.02
Improved clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a "chase" without decreased accumulation in the target tumor. J Nucl Med (1994) 1.01
RGD-labeled USPIO inhibits adhesion and endocytotic activity of alpha v beta3-integrin-expressing glioma cells and only accumulates in the vascular tumor compartment. Radiology (2009) 1.01
Molecular-functional imaging of cancer: to image and imagine. Trends Mol Med (2007) 1.00
Cellular compartmentalization of internalized paramagnetic liposomes strongly influences both T1 and T2 relaxivity. Magn Reson Med (2009) 0.98
Gadolinium-labeled liposomes containing various amphiphilic Gd-DTPA derivatives: targeted MRI contrast enhancement agents for the liver. Magn Reson Med (1991) 0.97
Anti-angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 0.96
Biochemical modification of streptavidin and avidin: in vitro and in vivo analysis. J Nucl Med (1996) 0.96
Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin North Am (2009) 0.94
A review: Integrin alphavbeta3-targeted molecular imaging and therapy in angiogenesis. Nanomedicine (2005) 0.93
Magnetic resonance spectroscopic imaging of tumor metabolic markers for cancer diagnosis, metabolic phenotyping, and characterization of tumor microenvironment. Dis Markers (2004) 0.93
Improved magnetic resonance molecular imaging of tumor angiogenesis by avidin-induced clearance of nonbound bimodal liposomes. Neoplasia (2008) 0.92
Activated clearance of a biotinylated macromolecular MRI contrast agent from the blood pool using an avidin chase. Bioconjug Chem (2003) 0.90
Thermosensitive paramagnetic liposomes for temperature control during MR imaging-guided hyperthermia: in vitro feasibility studies. Acad Radiol (2000) 0.90
Gadolinium-DTPA liposomes as a potential MRI contrast agent. Work in progress. Invest Radiol (1988) 0.88
The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. Clin Cancer Res (2002) 0.87
MAGfect: a novel liposome formulation for MRI labelling and visualization of cells. Org Biomol Chem (2006) 0.87
Mixed micelles containing lipophilic gadolinium complexes as MRA contrast agents. MAGMA (2001) 0.86
Endostatin's endpoints-Deciphering the endostatin antiangiogenic pathway. Cancer Cell (2004) 0.86
Kinetics of avidin-induced clearance of biotinylated bimodal liposomes for improved MR molecular imaging. Magn Reson Med (2008) 0.83
Integrins as targets of angiogenesis inhibition. Cancer J (2002) 0.83
Gadolinium-labeled liposomes containing amphiphilic Gd-DTPA derivatives of varying chain length: targeted MRI contrast enhancement agents for the liver. Magn Reson Imaging (1991) 0.82
Entrapment of gadolinium-DTPA in liposomes. Characterization of vesicles by P-31 NMR spectroscopy. Invest Radiol (1988) 0.81
Improved imaging of infections by avidin-induced clearance of 99mTc-biotin-PEG liposomes. J Nucl Med (2000) 0.79
Liposome delivery of NMR contrast agents for improved tissue imaging. Magn Reson Med (1986) 0.79
Soft tissue tumors: grading, staging, and tissue-specific diagnosis. Top Magn Reson Imaging (2007) 0.79
Relaxation enhancement using liposomes carrying paramagnetic species. Magn Reson Imaging (1984) 0.79
Liposomes containing paramagnetic macromolecules as MRI contrast agents. Magn Reson Med (1986) 0.78
Relaxivity and binding of Mn2+ ions in solutions of phosphatidylserine vesicles. Magn Reson Med (1988) 0.77
Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell (2006) 4.15
Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett (2008) 2.98
Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis (2008) 2.89
Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed (2006) 2.57
Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles. Radiology (2010) 2.43
Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol (2006) 2.33
1H MR spectroscopy of the brain: absolute quantification of metabolites. Radiology (2006) 2.26
Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A (2006) 2.26
Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res (2007) 2.13
MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J (2005) 2.03
Quantum dots with a paramagnetic coating as a bimodal molecular imaging probe. Nano Lett (2006) 1.98
Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice. Radiology (2005) 1.94
Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood (2006) 1.82
Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov (2011) 1.78
Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J (2006) 1.76
Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev (2007) 1.76
Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation (2008) 1.68
In vivo characterization of a new abdominal aortic aneurysm mouse model with conventional and molecular magnetic resonance imaging. J Am Coll Cardiol (2011) 1.65
Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity. J Control Release (2010) 1.63
Improved biocompatibility and pharmacokinetics of silica nanoparticles by means of a lipid coating: a multimodality investigation. Nano Lett (2008) 1.62
Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site. Cancer Lett (2007) 1.61
Determination of mouse skeletal muscle architecture using three-dimensional diffusion tensor imaging. Magn Reson Med (2005) 1.60
Nanotechnology in medical imaging: probe design and applications. Arterioscler Thromb Vasc Biol (2008) 1.55
Magnetic resonance imaging of vulnerable atherosclerotic plaques: current imaging strategies and molecular imaging probes. J Magn Reson Imaging (2007) 1.52
Diffusion tensor imaging of left ventricular remodeling in response to myocardial infarction in the mouse. NMR Biomed (2009) 1.51
Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res (2010) 1.50
Isolation of endothelial cells from fresh tissues. Nat Protoc (2008) 1.49
Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst (2004) 1.49
Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res (2005) 1.49
Multifunctional gold nanoparticles for diagnosis and therapy of disease. Mol Pharm (2013) 1.48
A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug Chem (2004) 1.47
Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. JACC Cardiovasc Imaging (2011) 1.46
Nanoparticulate assemblies of amphiphiles and diagnostically active materials for multimodality imaging. Acc Chem Res (2009) 1.42
Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res (2011) 1.40
Signalling pathways in vasculogenic mimicry. Biochim Biophys Acta (2010) 1.38
Paramagnetic lipid-coated silica nanoparticles with a fluorescent quantum dot core: a new contrast agent platform for multimodality imaging. Bioconjug Chem (2008) 1.37
Molecular imaging of tumor angiogenesis using alphavbeta3-integrin targeted multimodal quantum dots. Angiogenesis (2008) 1.37
Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res (2003) 1.37
DTI-based assessment of ischemia-reperfusion in mouse skeletal muscle. Magn Reson Med (2006) 1.35
An ApoA-I mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection. Small (2008) 1.34
Interferon-beta blocks infiltration of inflammatory cells and reduces infarct volume after ischemic stroke in the rat. J Cereb Blood Flow Metab (2003) 1.33
The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells. Am J Pathol (2008) 1.33
Integrin expression profiling identifies integrin alpha5 and beta1 as prognostic factors in early stage non-small cell lung cancer. Mol Cancer (2010) 1.31
High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.30
Magnetic and fluorescent nanoparticles for multimodality imaging. Nanomedicine (Lond) (2007) 1.28
Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. Mol Pharm (2010) 1.28
Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab (2004) 1.28
Dynamic MRS and MRI of skeletal muscle function and biomechanics. NMR Biomed (2006) 1.27
Skeletal muscle degeneration and regeneration after femoral artery ligation in mice: monitoring with diffusion MR imaging. Radiology (2007) 1.27
Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles. Magn Reson Med (2007) 1.25
Galectins in the tumor endothelium: opportunities for combined cancer therapy. Blood (2007) 1.24
Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Exp Cell Res (2004) 1.24
Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol (2002) 1.24
Multifunctional nanoemulsion platform for imaging guided therapy evaluated in experimental cancer. ACS Nano (2011) 1.23
Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J (2007) 1.23
A high relaxivity Gd(III)DOTA-DSPE-based liposomal contrast agent for magnetic resonance imaging. Eur J Pharm Biopharm (2008) 1.23
The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res (2003) 1.22
RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB J (2010) 1.21
The biological properties of iron oxide core high-density lipoprotein in experimental atherosclerosis. Biomaterials (2011) 1.21
Interferon-beta prevents cytokine-induced neutrophil infiltration and attenuates blood-brain barrier disruption. J Cereb Blood Flow Metab (2003) 1.21
Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res (2007) 1.20
MRI contrast agents: current status and future perspectives. Anticancer Agents Med Chem (2007) 1.19
Role of ischemia and deformation in the onset of compression-induced deep tissue injury: MRI-based studies in a rat model. J Appl Physiol (1985) (2007) 1.19
Comparison between prospective and retrospective triggering for mouse cardiac MRI. NMR Biomed (2007) 1.19
Increased intramyocellular lipid content but normal skeletal muscle mitochondrial oxidative capacity throughout the pathogenesis of type 2 diabetes. FASEB J (2008) 1.17
Synergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett (2010) 1.16
Iron oxide core oil-in-water emulsions as a multifunctional nanoparticle platform for tumor targeting and imaging. Biomaterials (2009) 1.15
Annexin A5-conjugated quantum dots with a paramagnetic lipidic coating for the multimodal detection of apoptotic cells. Bioconjug Chem (2006) 1.14
Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int J Cancer (2005) 1.13
Tumor targeting of MMP-2/9 activatable cell-penetrating imaging probes is caused by tumor-independent activation. J Nucl Med (2011) 1.13
Modified natural nanoparticles as contrast agents for medical imaging. Adv Drug Deliv Rev (2009) 1.12
The role of blood platelets in tumor angiogenesis. Biochim Biophys Acta (2010) 1.12
Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res (2006) 1.11
Evaluation of Gd(III)DTPA-terminated poly(propylene imine) dendrimers as contrast agents for MR imaging. NMR Biomed (2006) 1.11
Dual targeting of epigenetic therapy in cancer. Biochim Biophys Acta (2006) 1.11
An MR-compatible bicycle ergometer for in-magnet whole-body human exercise testing. Magn Reson Med (2010) 1.10